2024 World Conference on Lung Cancer (WCLC) - Posters-P4.07F.05 Low OLFM1/BMP6 Expression Identifies High-Risk Stage I Non-Squamous Non-Small Cell Lung Cancer after Pulmonary Resection

P4.07F.05 Low OLFM1/BMP6 Expression Identifies High-Risk Stage I Non-Squamous Non-Small Cell Lung Cancer after Pulmonary Resection

Back to course

Pdf Summary

The study investigates prognostic biomarkers for high-risk stage I non-squamous non-small cell lung cancer (NSCLC) following pulmonary resection, focusing on OLFM1 and BMP6 gene expressions. It aims to improve the identification of patients who might benefit from personalized perioperative treatment. <br /><br />The research was conducted in two stages involving NSCLC patients: a discovery phase identifying gene expressions linked to recurrence in 33 patients and a validation phase with an independent cohort of 149 patients. Researchers identified 101 differentially expressed genes and narrowed them to six (BMP6, KCNK3, NFASC, OLFM1, PEG3, TNXB) associated with disease recurrence, using RNA sequencing and analysis of tumor specimens. <br /><br />In multivariable analysis, lower expressions of BMP6 and OLFM1 were found to be independent predictors of poor prognosis, correlating significantly with recurrence-free survival and high-risk pathologic markers like pleural invasion and lymphatic/vascular invasion. These prognostic indicators were consistent when cross-referenced with TCGA lung adenocarcinoma data. <br /><br />Additionally, OLFM1/BMP6 status helps identify high-risk patients within those with epidermal growth factor receptor (EGFR) mutated conditions post-resection. No mutations were identified as prognostic markers in this study. The findings underscore the relevance of OLFM1 and BMP6 as biomarkers in discerning recurrence risks, suggesting potential roles in personalizing further adjuvant treatments for certain lung cancer patients.<br /><br />This research, funded by AstraZeneca, adds valuable insights into NSCLC prognostics, fostering advancements in tailored treatments for stage I NSCLC patients exhibiting poor prognostic gene expressions.

Asset Subtitle

Kenichi Suda

Meta Tag

Speaker Kenichi Suda

Topic Early-Stage NSCLC

Keywords

NSCLC

prognostic biomarkers

OLFM1

BMP6

gene expressions

recurrence

personalized treatment

RNA sequencing

EGFR mutation

lung cancer